Literature DB >> 28721538

[Methamphetamine : Epidemiology, clinical importance and sequelae of abuse].

N Arnaud1, R Thomasius2.   

Abstract

Methamphetamine (also known as meth and crystal meth) is a highly psychoactive synthetic amphetamine type stimulant, which falls under the German Federal Narcotics Law. The substance is similar to other stimulants but has distinct features with respect to psychoactive effects, clinical symptoms, user characteristics and short and long-term consequences including substance-induced problems and comorbidities. The consumption and misuse of crystal meth is still limited to certain regions in Germany; however, the substance causes significant clinical and public health concerns in the affected regions and beyond due to the associated high potential for misuse and dependence, neurotoxic and neurodegenerative effects as well as many other severe health risks. The new German guidelines for methamphetamine use disorders are now available to provide clinicians with the current knowledge on effective diagnostics and treatment planning.

Entities:  

Keywords:  Amphetamine type stimulants; Crystal meth; Guidelines; Methamphetamine use disorder; Stimulants

Mesh:

Substances:

Year:  2017        PMID: 28721538     DOI: 10.1007/s00115-017-0376-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  16 in total

1.  What matters in measuring methamphetamine-related cognitive impairments: 'abnormality detection' versus 'everyday import'?

Authors:  Doris E Payer; Andy C Dean; Isabelle Boileau
Journal:  Neuropsychopharmacology       Date:  2012-04       Impact factor: 7.853

Review 2.  [AWMF-guideline: cocaine-, amphetamine-, ecstasy- and hallucinogen-related disorders].

Authors:  R Thomasius; E Gouzoulis-Mayfrank; C Karus; H Wiedenmann; L Hermle; P M Sack; D Zeichner; U Küstner; A Schindler; A Krüger; S Uhlmann; K U Petersen; P Zapletalova; L Wartberg; C G Schütz; M Schulte-Markwort; J Obrocki; A Heinz; A Schmoldt
Journal:  Fortschr Neurol Psychiatr       Date:  2004-12       Impact factor: 0.752

3.  Psychiatric comorbidity in methamphetamine dependence.

Authors:  Ruth Salo; Keith Flower; Anousheh Kielstein; Martin H Leamon; Thomas E Nordahl; Gantt P Galloway
Journal:  Psychiatry Res       Date:  2010-11-04       Impact factor: 3.222

4.  The prevalence of psychotic symptoms among methamphetamine users.

Authors:  Rebecca McKetin; Jennifer McLaren; Dan I Lubman; Leanne Hides
Journal:  Addiction       Date:  2006-10       Impact factor: 6.526

5.  Mortality, causes of death, and health status among methamphetamine users.

Authors:  Diane M Herbeck; Mary-Lynn Brecht; Katherine Lovinger
Journal:  J Addict Dis       Date:  2014-11-21

Review 6.  The neurotoxicity of amphetamines during the adolescent period.

Authors:  Armanda Teixeira-Gomes; Vera Marisa Costa; Rita Feio-Azevedo; Maria de Lourdes Bastos; Félix Carvalho; João Paulo Capela
Journal:  Int J Dev Neurosci       Date:  2014-12-04       Impact factor: 2.457

7.  Methamphetamine for Hitler's Germany: 1937 to 1945.

Authors:  Ray J Defalque; Amos J Wright
Journal:  Bull Anesth Hist       Date:  2011-04

8.  Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence.

Authors:  Ari D Kalechstein; Thomas F Newton; Michael Green
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2003       Impact factor: 2.198

Review 9.  Developmental and behavioral consequences of prenatal methamphetamine exposure: A review of the Infant Development, Environment, and Lifestyle (IDEAL) study.

Authors:  Lynne M Smith; Sabrina Diaz; Linda L LaGasse; Trecia Wouldes; Chris Derauf; Elana Newman; Amelia Arria; Marilyn A Huestis; William Haning; Arthur Strauss; Sheri Della Grotta; Lynne M Dansereau; Charles Neal; Barry M Lester
Journal:  Neurotoxicol Teratol       Date:  2015-07-23       Impact factor: 3.763

Review 10.  Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms.

Authors:  Rosario Moratalla; Amit Khairnar; Nicola Simola; Noelia Granado; Jose Ruben García-Montes; Pier Francesca Porceddu; Yousef Tizabi; Giulia Costa; Micaela Morelli
Journal:  Prog Neurobiol       Date:  2015-10-09       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.